What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs
ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) to break down the molecules, clinical trials, weight loss results, and safety signals that could define the next generation of obesity and diabetes medicine.
We dive deep into Survodutide, Mazdutide, UBT251, Berobenatide (MET-097), CagriSema, Zenagamtide (formerly Amycretin), Petrelintide, and so much more!
From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever. Which therapies showed the strongest weight loss? Which struggled with tolerability? And what do these results mean for patients living with obesity, type 2 diabetes, MASLD, sleep apnea, and other metabolic diseases?
In this episode:
✅ Survodutide obesity and liver fat reduction data
✅ Mazdutide Phase 3 obesity and diabetes results
✅ UBT251 triple agonist weight loss data
✅ Berobenatide (MET-097) long-acting GLP-1 updates
✅ CagriSema diabetes and obesity trial results
✅ Zenagamtide (Amycretin) injectable and oral development
✅ Petrelintide amylin agonist info
✅ Future GLP-1, GIP, glucagon, and amylin therapies
The future of obesity medicine is no longer just about who produces the most weight loss. It’s about matching the right therapy to the right patient, improving tolerability, and addressing metabolic disease beyond the number on the scale.
Read more obesity medicine news at obesity.news
🔗 Linktree: linktr.ee/manonthemounjaro
#ADA2026 #Retatrutide #CagriSema #Survodutide #Mazdutide #UBT251 #Berobenatide #MET097 #Zenagamtide #Amycretin #Petrelintide #Inisepatide #Elcaglipron #GLP1 #ObesityMedicine #WeightLoss #Type2Diabetes #Zepbound #Mounjaro #Wegovy #GLP1News #ObesityResearch #DiabetesResearch #OnThePen
We dive deep into Survodutide, Mazdutide, UBT251, Berobenatide (MET-097), CagriSema, Zenagamtide (formerly Amycretin), Petrelintide, and so much more!
From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever. Which therapies showed the strongest weight loss? Which struggled with tolerability? And what do these results mean for patients living with obesity, type 2 diabetes, MASLD, sleep apnea, and other metabolic diseases?
In this episode:
✅ Survodutide obesity and liver fat reduction data
✅ Mazdutide Phase 3 obesity and diabetes results
✅ UBT251 triple agonist weight loss data
✅ Berobenatide (MET-097) long-acting GLP-1 updates
✅ CagriSema diabetes and obesity trial results
✅ Zenagamtide (Amycretin) injectable and oral development
✅ Petrelintide amylin agonist info
✅ Future GLP-1, GIP, glucagon, and amylin therapies
The future of obesity medicine is no longer just about who produces the most weight loss. It’s about matching the right therapy to the right patient, improving tolerability, and addressing metabolic disease beyond the number on the scale.
Read more obesity medicine news at obesity.news
🔗 Linktree: linktr.ee/manonthemounjaro
#ADA2026 #Retatrutide #CagriSema #Survodutide #Mazdutide #UBT251 #Berobenatide #MET097 #Zenagamtide #Amycretin #Petrelintide #Inisepatide #Elcaglipron #GLP1 #ObesityMedicine #WeightLoss #Type2Diabetes #Zepbound #Mounjaro #Wegovy #GLP1News #ObesityResearch #DiabetesResearch #OnThePen
Loading content...
Read the full transcript
Matterfact has every podcast on Apple Podcasts and Spotify: 700K+ channels, 120M+ episodes.
The candid version is on a podcast,
not the earnings call.
Matterfact turns the conversations your coverage is already having into a searchable, citable record — across every episode, not just this one.